The WIN-B is a Phase Ib/II investigator-sponsored trial (IST) that will evaluate the safety and preliminary efficacy of the Debiopharm's potent Wee-1 inhibitor Debio 0123 in combination with Gilead's
NORTHAMPTON, MA / ACCESSWIRE / May 28, 2024 / Gilead Sciences:In an effort to advance access to cancer prevention and early detection among U.S. workers, the Biden Cancer Moonshot recently announced a
Antibody Drug Conjugates Market Size, Trends and Future Scope Forecast 2023-2033 briefingwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from briefingwire.com Daily Mail and Mail on Sunday newspapers.
Hilltop Holdings Inc. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.0% in the 4th quarter, HoldingsChannel reports. The fund owned 24,716 shares of the biopharmaceutical company’s stock after selling 514 shares during the period. Hilltop Holdings Inc.’s holdings in Gilead Sciences were worth $2,002,000 as of its most recent filing […]